Introducing BioMarketSATM, a commercialization program for medical technology. Developed by BioMedSA and Cogent Consults, this groundbreaking initiative is designed to bridge the gap between startups and the hospital ecosystem, offering a direct pathway to technology adoption. Unlike traditional commercialization programs, this 6-week hybrid intensive—launching October 2025—dives deep into the hospital decision-making process, with a special focus on the Value Analysis Committee (VAC), the gatekeepers of hospital technology implementation. Through a mix of virtual and in-person sessions, participants will gain insider knowledge, strategic guidance, and hands-on training to confidently present their solutions to hospital stakeholders.
The initial cohort will focus on companies that have not yet begun commercial sales, but intend to sell to hospitals. The goal of the program is to help these companies identify the data they will need and how best to present it. At the conclusion of the program, participants will present simulated (not real) data to hospital VAC representatives to gain valuable feedback, ensuring they will be well-prepared when they enter the commercial market.
There is no charge to apply. Selected companies will pay a $500 program fee to join the cohort.
Questions? Contact info@biomedsa.org.
Follow BioMedSA on social media for FAQs and updates.
